Eurocine Vaccines´ Adjuvant Technology Endocine™ is evaluated with a vaccine candidate against COVID-19
Eurocine Vaccines has signed a Material Transfer Agreement regarding the evaluation of Endocine™ together with a vaccine candidate against COVID-19.Eurocine Vaccines has signed an evaluation agreement, a Material Transfer Agreement, with an innovative, North American, small public company, regarding the evaluation of Endocine™ together with a vaccine candidate against COVID-19. Studies in one or two animal species will be conducted to study both potency and safety.
Endocine™ is Eurocine Vaccines' proprietary adjuvant platform based on natural lipid compounds and formulated as a liposomal